Published in Blood on June 01, 2000
Treating childhood acute lymphoblastic leukemia without cranial irradiation. N Engl J Med (2009) 7.95
Ancestry and pharmacogenomics of relapse in acute lymphoblastic leukemia. Nat Genet (2011) 4.93
Activating Notch1 mutations in mouse models of T-ALL. Blood (2005) 3.08
Pediatric acute lymphoblastic leukemia: where are we going and how do we get there? Blood (2012) 2.82
Results of the Dana-Farber Cancer Institute ALL Consortium Protocol 95-01 for children with acute lymphoblastic leukemia. Blood (2006) 2.62
Outcomes after induction failure in childhood acute lymphoblastic leukemia. N Engl J Med (2012) 2.60
Molecular allelokaryotyping of pediatric acute lymphoblastic leukemias by high-resolution single nucleotide polymorphism oligonucleotide genomic microarray. Blood (2007) 2.31
Twenty-five-year follow-up among survivors of childhood acute lymphoblastic leukemia: a report from the Childhood Cancer Survivor Study. Blood (2008) 2.17
Mesenchymal cells regulate the response of acute lymphoblastic leukemia cells to asparaginase. J Clin Invest (2007) 2.05
Genome-wide association study identifies germline polymorphisms associated with relapse of childhood acute lymphoblastic leukemia. Blood (2012) 1.90
Acquired variation outweighs inherited variation in whole genome analysis of methotrexate polyglutamate accumulation in leukemia. Blood (2008) 1.89
Second malignant neoplasms and cardiovascular disease following radiotherapy. J Natl Cancer Inst (2012) 1.64
Shortening infusion time for high-dose methotrexate alters antileukemic effects: a randomized prospective clinical trial. J Clin Oncol (2011) 1.60
The favorable effect of activating NOTCH1 receptor mutations on long-term outcome in T-ALL patients treated on the ALL-BFM 2000 protocol can be separated from FBXW7 loss of function. Leukemia (2010) 1.56
Assessment of dexrazoxane as a cardioprotectant in doxorubicin-treated children with high-risk acute lymphoblastic leukaemia: long-term follow-up of a prospective, randomised, multicentre trial. Lancet Oncol (2010) 1.52
Folate pathway gene expression differs in subtypes of acute lymphoblastic leukemia and influences methotrexate pharmacodynamics. J Clin Invest (2005) 1.46
Pharmacogenetics of outcome in children with acute lymphoblastic leukemia. Blood (2005) 1.42
Impact of cytogenetics on the outcome of adult acute lymphoblastic leukemia: results of Southwest Oncology Group 9400 study. Blood (2007) 1.41
A 50-year journey to cure childhood acute lymphoblastic leukemia. Semin Hematol (2013) 1.32
NOTCH inhibition and glucocorticoid therapy in T-cell acute lymphoblastic leukemia. Leukemia (2009) 1.27
Central nervous system disease in hematologic malignancies: historical perspective and practical applications. Semin Oncol (2009) 1.21
Therapeutic advances in leukemia and myelodysplastic syndrome over the past 40 years. Cancer (2008) 1.18
Improved prognosis for older adolescents with acute lymphoblastic leukemia. J Clin Oncol (2010) 1.16
Polymorphisms of methylenetetrahydrofolate reductase (MTHFR) and susceptibility to pediatric acute lymphoblastic leukemia in a German study population. BMC Med Genet (2005) 1.15
Genetic variations in GRIA1 on chromosome 5q33 related to asparaginase hypersensitivity. Clin Pharmacol Ther (2010) 1.15
Therapeutic targeting of NOTCH1 signaling in T-cell acute lymphoblastic leukemia. Clin Lymphoma Myeloma (2009) 1.13
Association of genetic polymorphism in the folate metabolic pathway with methotrexate pharmacokinetics and toxicity in childhood acute lymphoblastic leukaemia and malignant lymphoma. Eur J Clin Pharmacol (2011) 1.10
Management of adult and paediatric acute lymphoblastic leukaemia in Asia: resource-stratified guidelines from the Asian Oncology Summit 2013. Lancet Oncol (2013) 1.07
Dose intensification of daunorubicin and cytarabine during treatment of adult acute lymphoblastic leukemia: results of Cancer and Leukemia Group B Study 19802. Cancer (2012) 1.06
Increased expression of miR-221 is associated with shorter overall survival in T-cell acute lymphoid leukemia. Exp Hematol Oncol (2013) 1.04
A genome-wide approach identifies that the aspartate metabolism pathway contributes to asparaginase sensitivity. Leukemia (2010) 1.03
Infections in a pediatric patient cohort with acute lymphoblastic leukemia during the entire course of treatment. Support Care Cancer (2005) 0.97
Functional protein network activation mapping reveals new potential molecular drug targets for poor prognosis pediatric BCP-ALL. PLoS One (2010) 0.96
A revised definition for cure of childhood acute lymphoblastic leukemia. Leukemia (2014) 0.95
Results of the hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone regimen in elderly patients with acute lymphocytic leukemia. Cancer (2008) 0.94
Low platelet counts after induction therapy for childhood acute lymphoblastic leukemia are strongly associated with poor early response to treatment as measured by minimal residual disease and are prognostic for treatment outcome. Haematologica (2011) 0.90
Hematopoietic stem cell transplantation for leukemia. Pediatr Clin North Am (2010) 0.90
Pediatric T-cell lymphoblastic leukemia evolves into relapse by clonal selection, acquisition of mutations and promoter hypomethylation. Haematologica (2015) 0.89
Neuropsychological outcomes of standard risk and high risk patients treated for acute lymphoblastic leukemia on Dana-Farber ALL consortium protocol 95-01 at 5 years post-diagnosis. Pediatr Blood Cancer (2011) 0.88
Predictive value of multidrug resistance proteins and cellular drug resistance in childhood relapsed acute lymphoblastic leukemia. J Cancer Res Clin Oncol (2007) 0.87
Markedly improved outcomes and acceptable toxicity in adolescents and young adults with acute lymphoblastic leukemia following treatment with a pediatric protocol: a phase II study by the Japan Adult Leukemia Study Group. Blood Cancer J (2014) 0.87
Hematopoietic stem cell transplantation for children with high-risk acute lymphoblastic leukemia in first complete remission: a report from the AIEOP registry. Haematologica (2013) 0.84
High-risk childhood acute lymphoblastic leukemia. Clin Lymphoma Myeloma (2009) 0.84
First-line treatment of acute lymphoblastic leukemia with pegasparaginase. Biologics (2009) 0.83
Association of ITPA genotype with event-free survival and relapse rates in children with acute lymphoblastic leukemia undergoing maintenance therapy. PLoS One (2014) 0.82
SNP Array in Hematopoietic Neoplasms: A Review. Microarrays (Basel) (2015) 0.82
Magnetic resonance imaging of the brain in survivors of childhood acute lymphoblastic leukemia. Oncol Lett (2012) 0.80
Induction of acute lymphocytic leukemia differentiation by maintenance therapy. Leukemia (2007) 0.80
Rapid engraftment of human ALL in NOD/SCID mice involves deficient apoptosis signaling. Cell Death Dis (2012) 0.80
Tumor necrosis factor and lymphotoxin-alpha genetic polymorphisms and risk of relapse in childhood B-cell precursor acute lymphoblastic leukemia: a case-control study of patients treated with BFM therapy. BMC Blood Disord (2001) 0.79
Current applications and different approaches for microbial l-asparaginase production. Braz J Microbiol (2016) 0.78
Potential roles of microRNA-29a in the molecular pathophysiology of T-cell acute lymphoblastic leukemia. Cancer Sci (2015) 0.78
Prediction of outcomes by early treatment responses in childhood T-cell acute lymphoblastic leukemia: a retrospective study in China. BMC Pediatr (2015) 0.78
TPMT genetic variations in populations of the Russian Federation. Pediatr Blood Cancer (2009) 0.78
Detection of central nervous system leukemia in children with acute lymphoblastic leukemia by real-time polymerase chain reaction. J Mol Diagn (2005) 0.78
PACSIN2 polymorphism is associated with thiopurine-induced hematological toxicity in children with acute lymphoblastic leukaemia undergoing maintenance therapy. Sci Rep (2016) 0.77
Molecular diagnostics, targeted therapy, and the indication for allogeneic stem cell transplantation in acute lymphoblastic leukemia. Adv Hematol (2011) 0.77
Targeting of hyperactivated mTOR signaling in high-risk acute lymphoblastic leukemia in a pre-clinical model. Oncotarget (2015) 0.77
DNA repair polymorphisms influence the risk of second neoplasm after treatment of childhood acute lymphoblastic leukemia. J Cancer Res Clin Oncol (2012) 0.77
Attenuated measles virus controls pediatric acute B-lineage lymphoblastic leukemia in NOD/SCID mice. Haematologica (2014) 0.76
Intrinsic and chemo-sensitizing activity of SMAC-mimetics on high-risk childhood acute lymphoblastic leukemia. Cell Death Dis (2016) 0.76
Immature Reticulocyte Fraction and Absolute Neutrophil Count as Predictor of Hemopoietic Recovery in Patients with Acute Lymphoblastic Leukemia on Remission Induction Chemotherapy. Turk J Haematol (2015) 0.75
The Frequency of HLA-A, HLA-B, and HLA-DRB1 Alleles in Patients with Acute Lymphoblastic Leukemia in the Turkish Population: A Case-Control Study. Turk J Haematol (2016) 0.75
PQJS380: a novel lead compound to induce apoptosis in acute lymphoblastic leukemia cells. Cancer Biol Ther (2013) 0.75
Outcome of Children with Standard-Risk T-Lineage Acute Lymphoblastic Leukemia-Comparison among Different Treatment Strategies. Pediatr Blood Cancer (2015) 0.75
Use of PEG-asparaginase in newly diagnosed adults with standard-risk acute lymphoblastic leukemia compared with E. coli-asparaginase: a retrospective single-center study. Sci Rep (2016) 0.75
Endocrinological and cardiological late effects among survivors of childhood acute lymphoblastic leukemia. Turk J Haematol (2013) 0.75
Risk factors for symptomatic osteonecrosis in childhood ALL: A retrospective study of a Slovenian pediatric ALL population between 1970 and 2004. Exp Ther Med (2016) 0.75
Influence of IL10 (G1082A) and TNFα (G308A) Polymorphisms on the Survival of Pediatric Patients with ALL. Leuk Res Treatment (2012) 0.75
Poor Response to Standard Chemotherapy in Early T-precursor (ETP)-ALL: A Subtype of T-ALL Associated with Unfavourable Outcome: A Brief Report. Indian J Hematol Blood Transfus (2014) 0.75
Intensive chemotherapy improved treatment outcome for Chinese children and adolescents with lymphoblastic lymphoma. Int J Clin Oncol (2008) 0.75
Ethical guidelines for investigations of experimental pain in conscious animals. Pain (1983) 17.70
Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas. NCI Sponsored International Working Group. J Clin Oncol (1999) 17.43
Defining opportunistic invasive fungal infections in immunocompromised patients with cancer and hematopoietic stem cell transplants: an international consensus. Clin Infect Dis (2001) 12.73
Incidence of development of factor VIII and factor IX inhibitors in haemophiliacs. Lancet (1992) 5.59
Dominant-negative mutations of CEBPA, encoding CCAAT/enhancer binding protein-alpha (C/EBPalpha), in acute myeloid leukemia. Nat Genet (2001) 4.79
Prognostic factors in Ewing's tumor of bone: analysis of 975 patients from the European Intergroup Cooperative Ewing's Sarcoma Study Group. J Clin Oncol (2000) 4.15
New insights to the MLL recombinome of acute leukemias. Leukemia (2009) 4.07
Proposals for the immunological classification of acute leukemias. European Group for the Immunological Characterization of Leukemias (EGIL). Leukemia (1995) 4.04
Prognostic value of minimal residual disease in acute lymphoblastic leukaemia in childhood. Lancet (1998) 3.91
Contemporary classification of histiocytic disorders. The WHO Committee On Histiocytic/Reticulum Cell Proliferations. Reclassification Working Group of the Histiocyte Society. Med Pediatr Oncol (1997) 3.83
Overexpression of the pseudoautosomal gene MIC2 in Ewing's sarcoma and peripheral primitive neuroectodermal tumor. Oncogene (1990) 3.74
Cellular resistance to actinomycin D in Chinese hamster cells in vitro: cross-resistance, radioautographic, and cytogenetic studies. Cancer Res (1970) 3.64
Revision of the 1990 working formulation for the classification of pulmonary allograft rejection: Lung Rejection Study Group. J Heart Lung Transplant (1996) 3.51
AML1-ETO downregulates the granulocytic differentiation factor C/EBPalpha in t(8;21) myeloid leukemia. Nat Med (2001) 3.47
Treatment of older patients with mantle-cell lymphoma. N Engl J Med (2012) 3.46
X-linked Wiskott-Aldrich syndrome in a girl. N Engl J Med (1998) 3.45
Mutations in the gene encoding neutrophil elastase in congenital and cyclic neutropenia. Blood (2000) 3.45
Concurrent Langerhans cell histiocytosis and myelodysplasia in children. Med Pediatr Oncol (2000) 3.24
Primary gastrointestinal non-Hodgkin's lymphoma: I. Anatomic and histologic distribution, clinical features, and survival data of 371 patients registered in the German Multicenter Study GIT NHL 01/92. J Clin Oncol (2001) 3.22
Mutations and prognosis in primary myelofibrosis. Leukemia (2013) 3.13
Purification and biochemical characterization of human pluripotent hematopoietic colony-stimulating factor. Proc Natl Acad Sci U S A (1985) 3.02
Activation of human macrophages. Comparison of other cytokines with interferon-gamma. J Exp Med (1984) 3.02
Mutations in the gene for the granulocyte colony-stimulating-factor receptor in patients with acute myeloid leukemia preceded by severe congenital neutropenia. N Engl J Med (1995) 2.85
Long-term results of five consecutive trials in childhood acute lymphoblastic leukemia performed by the ALL-BFM study group from 1981 to 2000. Leukemia (2009) 2.78
TTG-2, a new gene encoding a cysteine-rich protein with the LIM motif, is overexpressed in acute T-cell leukaemia with the t(11;14)(p13;q11). Oncogene (1991) 2.71
Mild hypothermia increases blood loss and transfusion requirements during total hip arthroplasty. Lancet (1996) 2.70
HLH-94: a treatment protocol for hemophagocytic lymphohistiocytosis. HLH study Group of the Histiocyte Society. Med Pediatr Oncol (1997) 2.59
c-mpl mutations are the cause of congenital amegakaryocytic thrombocytopenia. Blood (2001) 2.52
Prednisone response is the strongest predictor of treatment outcome in infant acute lymphoblastic leukemia. Blood (1999) 2.48
The Concise Guide to PHARMACOLOGY 2013/14: overview. Br J Pharmacol (2013) 2.48
Experimental visceral leishmaniasis: production of interleukin 2 and interferon-gamma, tissue immune reaction, and response to treatment with interleukin 2 and interferon-gamma. J Immunol (1987) 2.45
Chronic myelomonocytic leukemia in childhood: a retrospective analysis of 110 cases. European Working Group on Myelodysplastic Syndromes in Childhood (EWOG-MDS) Blood (1997) 2.40
Detection of chimeric BCR-ABL genes in acute lymphoblastic leukaemia by the polymerase chain reaction. Lancet (1991) 2.33
Standardized MRD quantification in European ALL trials: proceedings of the Second International Symposium on MRD assessment in Kiel, Germany, 18-20 September 2008. Leukemia (2009) 2.30
Interleukin 2 regulates the expression of Tac antigen on peripheral blood T lymphocytes. J Exp Med (1984) 2.26
Results of treatment for soft tissue sarcoma in childhood and adolescence: a final report of the German Cooperative Soft Tissue Sarcoma Study CWS-86. J Clin Oncol (1999) 2.25
Site-specific deletions involving the tal-1 and sil genes are restricted to cells of the T cell receptor alpha/beta lineage: T cell receptor delta gene deletion mechanism affects multiple genes. J Exp Med (1993) 2.23
Rapid molecular response during early induction chemotherapy predicts a good outcome in childhood acute lymphoblastic leukemia. Blood (2000) 2.21
Long-term results of four consecutive trials in childhood ALL performed by the ALL-BFM study group from 1981 to 1995. Berlin-Frankfurt-Münster. Leukemia (2000) 2.21
Laboratory tests of iron status: correlation or common sense? Clin Chem (1996) 2.19
Nervous outflow from the cat's foot during noxious radiant heat stimulation. Brain Res (1974) 2.18
Recombinant human granulocyte colony-stimulating factor. Effects on hematopoiesis in normal and cyclophosphamide-treated primates. J Exp Med (1987) 2.17
Chemotherapy in 998 unselected childhood acute lymphoblastic leukemia patients. Results and conclusions of the multicenter trial ALL-BFM 86. Blood (1994) 2.11
Multidisciplinary treatment of primary Ewing's sarcoma of bone. A 6-year experience of a European Cooperative Trial. Cancer (1988) 2.11
Facilitation at the frog neuromuscular junction during and after repetitive stimulation. Pflugers Arch Gesamte Physiol Menschen Tiere (1966) 2.09
Serum S-100B protein in severe head injury. Neurosurgery (1999) 2.08
Mutations in ribosomal protein S19 gene and diamond blackfan anemia: wide variations in phenotypic expression. Blood (1999) 2.07
Role of ploidy, chromosome 1p, and Schwann cells in the maturation of neuroblastoma. N Engl J Med (1996) 2.05
Paraneoplastic hypokalemia in acute myeloid leukemia: a case of renin activity in AML blast cells. Ann Hematol (1996) 2.05
Single unit responses and the total afferent outflow from the cat's foot pad upon mechanical stimulation. Exp Brain Res (1968) 2.04
Pleuro-pulmonary blastoma: a case report and review of the literature. Med Pediatr Oncol (1995) 2.02
Reduction of wound infections in laparoscopic-assisted colorectal resections by plastic wound ring drapes (REDWIL)?--A randomized controlled trial. Langenbecks Arch Surg (2012) 2.01
Localized Ewing tumor of bone: final results of the cooperative Ewing's Sarcoma Study CESS 86. J Clin Oncol (2001) 2.01
In vitro cellular drug resistance in children with relapsed/refractory acute lymphoblastic leukemia. Blood (1995) 2.00
Myelodysplasia and acute myelogenous leukemia in Down's syndrome. A report of 40 children of the AML-BFM Study Group. Leukemia (1996) 1.96
Intensive ALL-type therapy without local radiotherapy provides a 90% event-free survival for children with T-cell lymphoblastic lymphoma: a BFM group report. Blood (2000) 1.93
Malignant peripheral neuroectodermal tumors. A retrospective analysis of 42 patients. Cancer (1988) 1.92
Screening for MLL tandem duplication in 387 unselected patients with AML identify a prognostically unfavorable subset of AML. Leukemia (2000) 1.91